Provided by Tiger Trade Technology Pte. Ltd.

Amphastar Pharmaceuticals

21.60
-0.0800-0.37%
Post-market: 21.600.00000.00%19:30 EDT
Volume:376.56K
Turnover:8.16M
Market Cap:918.82M
PE:12.80
High:22.20
Open:21.64
Low:21.44
Close:21.68
52wk High:31.26
52wk Low:16.65
Shares:42.54M
Float Shares:30.52M
Volume Ratio:0.94
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.69
EPS(LYR):2.03
ROE:10.30%
ROA:5.11%
PB:1.20
PE(LYR):10.64

Loading ...

Stock Track | Amphastar Pharmaceuticals Plunges 16.73% After-Hours on Q1 Earnings Miss, Lower Prices and Higher Costs

Stock Track
·
May 08

Amphastar Q1 revenue and adjusted EPS miss estimates

Reuters
·
May 08

Amphastar Q1 GAAP net income falls 75% to $6.4 million; revenue rises 0% to $171.2 million

Reuters
·
May 08

BRIEF-Amphastar Pharmaceuticals Q1 EPS USD 0.14

Reuters
·
May 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Amphastar Pharmaceuticals to report first-quarter earnings after market close, host conference call

Reuters
·
Apr 30

Amphastar Pharmaceuticals Cut to Hold From Buy by Jefferies

Dow Jones
·
Apr 22

Jefferies Downgrades Amphastar Pharmaceuticals to Hold From Buy, Adjusts Price Target to $22 From $30

MT Newswires Live
·
Apr 21

Amphastar downgraded to Hold from Buy at Jefferies

TIPRANKS
·
Apr 21

Amphastar Pharmaceuticals announces annual shareholder meeting

Reuters
·
Apr 14

Amphastar Pharmaceuticals Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Apr 08

Amphastar executives present at Needham Healthcare Conference webcast

Reuters
·
Apr 06

BRIEF-Amphastar Pharmaceuticals Inc - Authorizes $50 Million Increase To Share Buyback Program On March 12, 2026 - SEC Filing

Reuters
·
Mar 16

Amphastar Pharmaceuticals Inc - Authorizes $50 Mln Increase to Share Buyback Program on March 12, 2026 - SEC Filing

THOMSON REUTERS
·
Mar 16

Amphastar Pharmaceuticals publishes investor presentation outlining shift to proprietary and biosimilar drug pipeline mix at 85%

Reuters
·
Mar 11

BRIEF-Amphastar Pharmaceuticals- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC Filing

Reuters
·
Mar 07

Amphastar Pharmaceuticals: on March 3, Co & Nanjing Hanxin Pharmaceutical Technology Entered Into Amendment to Contract Research Agreement

THOMSON REUTERS
·
Mar 07

Amphastar Pharmaceuticals Inc - Supply Agreement Effective for Five Years With Payments in Chinese Yuan - SEC Filing

THOMSON REUTERS
·
Mar 07

Amphastar Pharmaceuticals: Pursuant to Amendment, Co to Use Research Cell Banks That Hanxin Develops to Make Master Cell Banks for AMP-105

THOMSON REUTERS
·
Mar 07

Amphastar Signs New Executive Employment Agreements With Liawatidewi and Zhou

Reuters
·
Mar 07